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INTRODUCTION
The ENESTnd randomised controlled trial demonstrated that nilotinib in 
newly diagnosed Philadelphia chromosome positive (Ph+) chronic phase 
chronic myeloid leukaemia (CML) has clinical superiority in terms of 
molecular and cytogenetic response over imatinib.[1,2] However the exact 
relationship between improvements in major molecular response (MMR), 
complete cytogenetic response (CCyR) and improvements in long-term 
survival is as yet unknown.
The objectives were:
1.  to evaluate the survival benefit of first-line nilotinib compared to  
first-line imatinib for the treatment of Ph+ chronic phase CML.
2.  to develop a decision analytic model which avoids the uncertainty of 
using surrogate response outcomes in economic evaluations.
Population: Adult patients with Ph+ CML diagnosed in chronic phase  
and who do not initially receive a stem cell transplant (SCT).
Intervention: Nilotinib 300 mg twice a day (b.i.d.)
Comparator: Imatinib 400 mg every day (q.d.)
Outcomes: Costs, life-years (LYs), quality-adjusted life-years (QALYs), 
incremental cost effectiveness ratios (ICERs).
Perspective: UK National Health Service (NHS) and Personal Social 
Services (PSS).
MATERIALS AND METHODS 
A decision analytic model of first-line nilotinib compared to first-line imatinib 
was constructed for newly diagnosed chronic phase Ph+ CML patients. Time 
on treatment data from the ENESTnd trial was used to model the effectiveness 
of nilotinib and imatinib. This approach allows the explicit modelling of all 
treatment failures (patients who fail to achieve or lose response, experience 
intolerable adverse events or those who discontinue treatment) and provides a 
measure of those that continue to benefit from treatment.
Patients enter the model in chronic phase (CP). The model estimates when 
one treatment will fail and hence the patient is switched to an alternative 
treatment. At each cycle, patients have a probability of remaining on current 
treatment, progressing to an alternative treatment or dying (Figure 1).  
Patients are able to remain in CP, accelerated phase (AP) or blastic phase 
(BP) for more than one cycle and they may die from other causes at any 
time. Patients that receive transplant may die from transplant-related 
mortality or remain well. Patients that are treated with HU have a probability 
of progressing to AP. On progression to AP or BP, all patients are assumed 
to receive HU therapy. Patients in AP have a probability of progressing to 
BP, and finally from BP to CML-related mortality. Patients may die from  
non-CML-related mortality at any time. 
Survival Estimates: The clinical effectiveness of first-line treatment 
was modelled using time on treatment data from the ENESTnd trial. This 
approach allows the explicit modelling of all treatment failures (patients who 
fail to achieve or lose response, experience intolerable adverse events, or 
those who discontinue treatment for other reasons) and directly reflects the 
costs associated with being on treatment.
In order to model time on treatment over the long term, a Weibull curve 
was fitted using regression analysis to a Kaplan-Meier curve of time on 
treatment from the ENESTnd trial based upon the numbers at risk and the 
numbers of events within the nilotinib arm (300 mg b.i.d.) and the imatinib 
arm (400 mg q.d.) (Figure 2). This method appropriately characterises the 
uncertainty in the data by fitting the curve more closely to data points with 
large numbers at risk and less censoring.
Figure 2. Kaplan-Meier estimate of time on treatment for ENESTnd trial 
24 month primary analyses. STI571 = imatinib; AMN107 = nilotinib
Costs: Costs (Sterling, 2011) associated with the different drug therapies, 
stem cell transplantation, routine hospital appointments for administration 
and monitoring, and treatment for severe adverse events were included 
(Table I). A patient access scheme is available for first-line nilotinib therapy 
and was included in the analysis.
Utilities: EQ-5D utilities were applied to patients in each health state (Figure 
1) and utility decrements were estimated for patients experiencing severe 
(grade 3 and 4) adverse events on TKI therapy (Table I).
RESULTS
The mean undiscounted survival was estimated to be 11.80 years in the 
nilotinib arm compared to 10.44 years in the imatinib arm; a difference of 
1.36 LYs (Table II). Using a discounting rate of 3.5%, patients are estimate to 
accrue an additional 0.88 LYs in the nilotinib arm compared to the imatinib 
arm. After adjusting for quality of life, patients are estimated to gain an 
additional 0.70 QALYs (discounted) in the nilotinib arm compared to the 
imatinib arm at a cost per QALY gained of £4,500 (discounted).
CONCLUSIONS
	 	•		 The results suggest that nilotinib produces 
substantially greater long-term survival and 
QALY gains than treatment with imatinib. 
	 	•		 The health benefits of nilotinib can be 
achieved at a marginal incremental cost 
which is well below a cost-effectiveness 
threshold of £20,000 per QALY gained.
	 	•		 The use of time on treatment data avoids 
the need for surrogate response outcomes 
and their associated uncertainty.
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Table I. Treatment costs, utilities and disutilities included in the model
Parameter Value Source
Costs
Nilotinib 300 mg (28 days) £2,432.85 [3]
Imatinib 400 mg (30 days) £1,724.39 [4]
HU 500mg (25 days) £10.47 [4]
Allogeneic SCT £99,224.38 [5,6]
Utilities
Chronic phase utility 0.854 [7]
Accelerated phase utility 0.595 [7]
Blastic phase utility 0.595 [7]
Transplant utility 0.813 Calculated*
Disutilities
Nilotinib disutility 0.010 Calculated*
Imatinib disutility 0.016 Calculated*
HU disutility 0 Assumption
*Based on the frequency and duration of serious adverse events. HU = hydroxyurea;  
SCT = stem cell transplantation.
Table II. Cost-effectiveness results from the probabilistic sensitivity 
analysis (PSA)
Parameter LYs QALYs Lifetime costs
Undiscounted
Nilotinib 11.80 9.02 £213,500
Imatinib 10.44 7.97 £202,700
Difference 1.36 1.06 £10,800
ICER £8,000 £10,300
Discounted
Nilotinib 8.98 6.95 £174,200
Imatinib 8.09 6.25 £171,100
Difference 0.88 0.70 £3,100
ICER £3,600 £4,500  
Costs rounded to nearest hundred. ICER = incremental cost-effectiveness ratio;  
LYs = life-years; QALYs = quality-adjusted life-years.
Figure 1. Conceptual model
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